AIMT News and Press, Aimmune Therapeutics Inc. From 04/30/19

Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas, M.D., President and Chief Executive Officer, will present at the Needham & Company 18 th Annual Healthcare Conference...

Aimmune (AIMT) had very good news on Monday, after it had announced a successful phase 3 study from Europe dealing with peanut allergy. The success of this study will allow for a regulatory filing in the European Union in the coming months. The biotech is also awaiting for its review of th...

Aimmune Therapeutics (NASDAQ: AIMT ) is up  9%  premarket on light volume in response to successful result s from a European Phase 3 clinical trial, ARTEMIS , evaluating lead candidate AR101 for the treatment of peanut allergy. More news on: Aimmune Therapeutics, Inc., Healthca...

-- Company Intends to Submit European MAA in Mid-2019 -- -- Webcast and Conference Call Today at 8:30 a.m. EDT -- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its phase 3 Eur...

Aimmune Therapeutics ( AIMT -4.8% ) is down on below-average volume in reaction to the FDA's review period for AR101 for peanut allergy. More news on: Aimmune Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

-- If Approved, AR101 Will Be the First Medicine for This Life-Threatening Condition -- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that the Biologics License Application (BLA) for AR...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in three upcoming investor conferences in March: Event: Cowen and Com...

Aimmune Therapeutics, Inc. (AIMT) Q4 2018 Earnings Conference Call February 28, 2019 5:00 PM ET Company Participants Laura Hansen – Vice President of Investor Relations Jayson Dallas – President and Chief Executive Officer Daniel Adelman – Chief Medical Offic...

Aimmune Therapeutics (NASDAQ: AIMT ): Q4 GAAP EPS of -$0.95 misses by $0.04 . More news on: Aimmune Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...